Tenaya TherapeuticsTNYA
TNYA
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
53% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 19
50% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]
11% less funds holding
Funds holding: 95 [Q3] → 85 (-10) [Q4]
17% less call options, than puts
Call options by funds: $266K | Put options by funds: $321K
17.98% less ownership
Funds ownership: 73.08% [Q3] → 55.1% (-17.98%) [Q4]
32% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 28
44% less capital invested
Capital invested by funds: $111M [Q3] → $62.4M (-$48.9M) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
625%
upside
Avg. target
$8.60
1,147%
upside
High target
$18
2,509%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Canaccord Genuity Whitney Ijem 26% 1-year accuracy 11 / 43 met price target | 770%upside $6 | Buy Maintained | 13 Mar 2025 |
Morgan Stanley Matthew Harrison 46% 1-year accuracy 11 / 24 met price target | 625%upside $5 | Overweight Maintained | 12 Mar 2025 |
Chardan Capital Geulah Livshits 17% 1-year accuracy 10 / 60 met price target | 1,205%upside $9 | Buy Maintained | 12 Mar 2025 |
HC Wainwright & Co. Joseph Pantginis 23% 1-year accuracy 94 / 411 met price target | 625%upside $5 | Buy Maintained | 11 Mar 2025 |
HC Wainwright & Co. Emily Bodnar 22% 1-year accuracy 36 / 161 met price target | 2,509%upside $18 | Buy Reiterated | 3 Feb 2025 |
Financial journalist opinion
Based on 7 articles about TNYA published over the past 30 days
Neutral
GlobeNewsWire
3 days ago
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models
SOUTH SAN FRANCISCO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the publications of positive preclinical data for TN-201, the company's gene therapy candidate for Myosin-Binding Protein C3 (MYBPC3)-associated hypertrophic cardiomyopathy (HCM), in Nature Communications.
Neutral
GlobeNewsWire
1 week ago
Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session
Late Breaker Oral Presentation to Include New Data from Cohort 1 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 Late Breaker Oral Presentation to Include New Data from Cohort 1 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201
Neutral
24/7 Wall Street
2 weeks ago
Insiders Are Loading Up on These 4 Biotech Stocks Now
Things are heating up in the biotechnology space, with a flurry of recent initial public offerings and some notable insider purchases of the past week or so.
Neutral
GlobeNewsWire
2 weeks ago
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
Neutral
GlobeNewsWire
3 weeks ago
Tenaya Therapeutics Announces Pricing of Public Offering
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten public offering of 75,000,000 total units for gross proceeds of approximately $52.5 million prior to deducting underwriting discounts and commissions and offering expenses.
Neutral
GlobeNewsWire
3 weeks ago
Tenaya Therapeutics Announces Proposed Public Offering
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it intends to offer and sell units consisting of common stock and Series A warrants and Series B warrants, each to purchase shares of common stock. Tenaya may also sell to certain investors, in lieu of units, pre-funded units consisting of pre-funded warrants to purchase shares of common stock at a purchase price of $0.001 per share, Series A warrants and Series B warrants. The pre-funded warrants will be immediately exercisable and will not expire. All of the securities in this offering will be sold by Tenaya. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Neutral
GlobeNewsWire
3 weeks ago
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya's Chief Executive Officer, will participate in TD Cowen's 45th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference 2025. Details are as follows:
Neutral
GlobeNewsWire
1 month ago
Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine
Funding will Support Ongoing RIDGE™ -1 Clinical Trial of TN-401 Gene Therapy for the Potential Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
Neutral
GlobeNewsWire
2 months ago
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones
Continued Focus on Driving Advancement of TN-201 and TN-401 Gene Therapies for Cardiomyopathies Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy Additional Cohort 1 Data to be Reported in 1H25 Building on Promising Initial Data Initial Data from RIDGE™-1 Phase 1b Clinical Trial of TN-401 for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Expected in 2H25 SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today provided an update on its clinical development programs and outlined its strategic priorities for 2025.
Neutral
GlobeNewsWire
3 months ago
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024
Company to host conference call on Tuesday, December 17, at 8:00 a.m. ET Company to host conference call on Tuesday, December 17, at 8:00 a.m. ET
Charts implemented using Lightweight Charts™